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ABSTRACT Tumor necrosis factor alpha (TNF-α) inhibitors revolutionized the man-
agement of patients affected by autoimmune diseases such as inflammatory bowel 
diseases, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and pso-
riasis. The biologic agents targeted to block TNF-α such as infliximab, adalimumab, 
certulizumab pegol, etanercept, and golimumab, have a good safety profile; how-
ever, with increasing, broader, and prolonged use, patients could be exposed to an 
increased risk of adverse reactions including a wide spectrum of dermatological 
conditions of different etiology and morphology. Among these, of particular in-
terest is the development of skin immune-mediated diseases that seem to be the 
consequence of the paradoxical inflammation induced by anti-TNF-α therapy. The 
majority of these lesions are identified as psoriasiform with three main morpholo-
gies and different frequency: pustular psoriasis, signs of psoriasis, and guttate; al-
though erythrodermic or inverted psoriasis, among others, may be observed with 
less frequency.  The increased incidence of these dermatological immune-mediated 
lesions highlight the importance of the skin as a main target of the side effect of 
anti-TNF-α agents, while the immunopathogenetic hypothesis of these paradoxical 
effects are quite intriguing. The aim of this review is to collect and to analyze exist-
ing knowledge to better understand the pathogenetic mechanism of these compli-
cations and suggest new fields of investigation, improve therapeutic strategies of 
autoimmune diseases, and prevent and/or better address such complications.
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INTRODUCTION
Since the late 1990s, the therapeutic approach to 
rheumatologic conditions, such as rheumatoid arthri-
tis and seronegative arthritis, has changed dramati-
cally with the introduction of biological therapies such 
as tumor necrosis factor alpha (TNF-α) inhibitors (1,2). 
Over the years, numerous publications have demon-
strated their efficacy against chronic inflammatory 
diseases and their relative safety, and consequently 
the use of anti-TNF-α agents in patients with several 
immune-mediated inflammatory diseases, not only in 
the field of rheumatology, is increasing (3). Neverthe-
less, in parallel with their spread, rising numbers of 
pharmacological monitoring reports have described 
their association with unusual reactions, namely 
the de novo development or flaring of conditions 
that usually respond to these therapeutic agents, 
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including psoriasiform eruption. Due to the aston-
ishing nature of this induced dermopathy, as TNF-
α inhibitors are also largely and successfully used 
in the treatment of psoriasis, the term paradoxical 
psoriasis has been coined (4).
OVERVIEW
In 2004, the first case of anti-TNF-α agent (inflix-
imab) induced psoriatic lesions was described in a pa-
tient with Crohn’s disease (5). A few months later, the 
British Journal of Dermatology reported two unusual 
cases of cutaneous psoriatic lesions appearing in pa-
tients with rheumatoid arthritis treated with TNF-α in-
hibitors (in one case etanercept and in the other inflix-
imab) (6). Afterwards, the British Society for Rheuma-
tology Biologics Registry notified, from the beginning 
(January 2001) until the end of the observation (July 
2007), 25 cases among a group of 9826 patients who 
developed new onset of psoriasis as a consequence of 
anti-TNF-α treatment. In the comparison group of 2880 
patients treated with the traditional disease-modify-
ing antirheumatic drugs (DMARDs), none developed 
psoriasis during the same observation period. This 
prospective study also detected a higher incidence of 
paradoxical reactions in patients treated with adalim-
umab (7). However, the latter has not been confirmed 
in subsequent studies.  In the meantime, Wollina et al. 
(8) reported 116 patients from the literature plus six 
new patients (three men and three women) who de-
veloped psoriatic skin lesions during treatment with 
anti-TNF-α agents. Subsequently, Collamer and Batta-
farano (9) reported 207 cases of psoriasis induced by 
TNFα inhibitors until August 2009, while at almost the 
same time a French study (10) found 57 cases in the 
National Pharmacovigilance Database. More recently, 
Shmidt et al. (11) reviewed 56 additional cases from 
the Mayo Clinic between January 1998 and July 2010 
and determined the prevalence of plaques (48% of 
cases) and palmoplantar pustulosis (45%). Lately, with 
the increased use of anti-TNF-α in the treatment of in-
flammatory bowel diseases, two studies (12,13) evalu-
ated the induction of psoriasis by anti-TNF-α agents 
in these patients, and several case reports have been 
published on the appearance of psoriatic skin lesions 
in patients taking TNF-α inhibitors for other immuno-
logical diseases, such as SAPHO syndrome, juvenile ar-
thritis, and Behcet’s disease (14,15). All the aforemen-
tioned studies assessed the three classical anti-TNF-α 
agents (infliximab, adalimumab, and etanercept), 
however, after the appearance of certolizumab (16) 
and golimumab (17) there have been case reports of 
paradoxical psoriasis associated also with the use of 
these new anti-TNF-α agents, suggesting a class effect 
rather than a drug-specific effect.
According to data from rheumatology literature, 
psoriasiform eruptions induced by anti-TNF-α have a 
low incidence rate (1.04-3.0 per 1 000 person-years) 
and a prevalence ranging from 0.6% to 5.3%, depend-
ing on the different studies, that clearly exceeds the 
1-2% prevalence expected by chance (18,19). No sta-
tistically significant predisposing factors or effect of 
personal or family history of psoriasis have yet been 
identified, but it is likely that genetic susceptibility 
could have a role in these paradoxical reactions. Men 
and women appear to be equally affected, and no pre-
dilection for any age group has been described, with 
some reports in children as well (20). The slight sex dis-
crepancy found in some reviews is probably due to the 
prevalence of women in the distribution of primary 
diseases for which anti-TNF-α agents have been used 
(21). Concomitant treatment with other immunosup-
pressive drugs for psoriasis has not proven effective 
as a preventive measure for the development of these 
skin lesions. Regarding the clinical presentation, the 
typical manifestations are plaques and pustular pso-
riasis with palmoplantar involvement, but develop-
ment of guttate psoriasis and psoriasis of the nail and 
scalp with alopecia have also been described (22,23). 
Reports are also heterogeneous with regards to the 
most frequent underlying disease, although most of 
the cases found in the literature concern patients af-
fected by rheumatoid arthritis. Likewise, authors do 
not agree on the type of anti-TNF-α agent more closely 
related with the induction of psoriasis. Some review-
ers found higher incidence of psoriatic skin lesions in 
patients treated with monoclonal antibodies (such as 
infliximab and adalimumab) while others proposed 
that monoclonal antibodies could be more commonly 
associated with the development of de novo psoriasis 
and etanercept with the worsening of pre-existent 
psoriasis (24). The treatment duration before the ap-
pearance of skin lesions also seems extremely variable, 
although the reaction tends to occur after the first two 
weeks of treatment, helping to distinguish this condi-
tion from a hypersensitivity drug reaction.
To date, the underlying pathophysiological 
mechanism by which TNF-α blockade therapy could 
induce the development of psoriasis is still obscure, 
although several theories have been proposed to ex-
plain this immunologic phenomenon. The full action 
of anti-TNF-α agents probably changes the balance 
between regulatory and inflammatory cytokines and 
cells, disrupting the homeostasis of the skin.
Initially, some authors considered these skin le-
sions a hypersensitivity reaction, but then skin biop-
sies of selected cases ruled out this theory, having 
shown the same histological lesions present in indi-
viduals with idiopathic psoriasis (25). 
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Other authors postulated that these cases could 
be a misdiagnosis and that they were actually patients 
with psoriatic arthritis with a later onset of the skin in-
volvement. However, the majority of cases referred to 
patients with a definite diagnosis of rheumatoid ar-
thritis or spondyloarthropathies. Moreover, the coex-
istence of psoriasis with other rheumatic inflammato-
ry diseases, such as rheumatoid arthritis, is extremely 
rare, while psoriasis induced by TNF-α inhibitors has 
been reported with a much higher incidence. 
One of the most plausible hypotheses suggests 
the disruption of the balance between TNF-α and in-
terferon-α (INF-α). Indeed, TNF-α inhibits both matu-
ration of plasmacytoid dendritic cells, known to be 
the natural INF-α producing cells, and release of INF-
α (26), the latter recently having been proven to be a 
pivotal cytokine in the early phase of psoriasis (27). 
The onset and the worsening of psoriasis after injec-
tion of recombinant IFN-α has been demonstrated, 
corroborating the association between psoriasis and 
IFN-α (28). Furthermore, plasmacytoid dendritic cells 
have been shown to infiltrate the skin in patients with 
psoriasis and release IFN-α (29). Moreover, the IFN-α 
signaling pathway is also activated in these patients 
(30), and it seems that T-cells in psoriatic skin acquire 
an increased sensitivity to IFN-α (31). IFN-α seems 
to also increase T-cell expression of chemokine re-
ceptors, such as CXCR3, promoting the migration of 
autoreactive T-cells to the psoriatic dermis and con-
sequently causing skin damage (32). The central role 
of INF-α in the induction of psoriatic skin lesions was 
suggested because of the cross-regulation between 
TNF-α and IFN-α, which means that TNF-α blockade 
may lead to IFN-α over-expression with consequent 
onset of psoriasis. In support of this theory, one 
study (33) reported higher levels of perivascular and 
epidermal myxovirus-resistance protein A (MxA), an 
indicator of local IFN-α release, in the inflammatory 
cells of skin samples of psoriasis induced by anti-TNF-
α compared to samples of psoriasis vulgaris.
An injury or superinfection (mainly bacterial in-
fection) on the inflammatory lesion may also have 
a key role by inducing IFN-α production in plasma-
cytoid dendritic cells (34). It has been proposed that 
palmopustular lesions could indeed represent a form 
of keratoderma blenorrhagicum elicited by persistent 
Yersinia or Chlamydia (35).
Finally, according to another possible hypothesis, 
anti-TNFα agents may induce a disruption of the im-
mune system equilibrium, enhancing Th17 function 
and down-regulating Treg expansion (36).
Psoriasiform skin lesions induced by TNF-α may 
be caused by a combination of all these mechanisms, 
which may differ in magnitude from patient to pa-
tient. However, it may be that TNF-α is not solely in-
volved, but that other cytokine and T-cell pathways 
are potential key players, in the pathogenesis of 
this paradoxical effect, explaining the appearance 
of psoriasiform lesions, although rarely, in patients 
treated with different biological therapy such as ritux-
imab (37,38), anakinra (39), and tocilizumab (40). Fur-
thermore, while it is true that the anti-TNF-α agents 
can induce the occurrence of psoriasiform reactions 
in patients with arthritis, the opposite scenario is 
also true. Indeed, unusual cases of arthritis induced 
by anti-TNF-α in patients with psoriasis vulgaris have 
been reported in the literature (41,42). It is evident 
that further studies are required to better clarify the 
pathophysiology of this unexpected skin reaction in 
patients undergoing biological treatment.
TREATMENT APPROACH
To date, no guidelines exist for treating pso-
riasis induced by anti-TNF-α agents, so finding an 
effective treatment can be extremely challenging. It 
is imperative to exclude infection, and close collabo-
ration with a dermatologist is recommended since a 
skin biopsy can be of value to rule out other possible 
causes and a variety of cutaneous therapies are often 
required. 
There is a wide range of therapeutic approach-
es. All patients should remain under close and con-
tinual surveillance, and the appearance of skin com-
plications should receive the utmost attention. The 
appearance of psoriasiform lesions can be treated 
using several treatment modalities, ranging from sus-
pension of the offending anti-TNF-α agent to topical 
and systemic therapies to avoid the discontinuation 
of an effective treatment.
Collamer et al. (9) proposed a therapeutic algo-
rithm based on the severity of psoriasis. In cases of skin 
eruptions affecting less than 5% of body surface area, 
a topical treatment (corticosteroids, keratolytics, and 
vitamin D analogs) should be recommended without 
withdrawing the TNF-α inhibitor. For more severe sys-
temic reactions covering more than 5% of body area, 
or in case of pustular psoriasis and unsuccessful topi-
cal treatment, the addition of systemic therapy includ-
ing methotrexate, retinoids, and cyclosporine or PUVA 
may be beneficial in treating psoriatic lesions. Discon-
tinuation of the anti-TNF-α agent, which usually results 
in a complete or partial resolution of the skin lesions 
in the majority of cases, should be taken into account 
in patients who do not respond to the previous treat-
ment and develop severe psoriasis or erythrodermic 
presentation, and also when skin lesions reduce the 
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quality of life or tend to increase in size and severity 
after each injection treatment. 
With regard to the switch to another anti-TNF-α 
agent, this therapeutic approach is not recommend-
ed by all authors since this paradoxical reaction is a 
class effect with a high risk of reappearance of the 
skin lesions when using another anti-TNF-α agent, al-
though the recurrence rate varies among the case se-
ries (48-85% ). Ustekinumab has recently been used 
effectively in several cases of refractory palmoplan-
tar pustulosis induced by anti-TNF-α agents (43), 
although an exacerbation of infliximab-induced 
palmoplantar psoriasis in a patient with ankylosing 
spondylitis has also been reported (44). 
Interestingly, according to Werner de Castro et 
al. (45) vitamin D may have a therapeutic role in the 
treatment of psoriasis induced by anti-TNF-α agents. 
CONCLUSION
In conclusion, it seems a paradox that TNF-α in-
hibitors, which are widely used in the therapy of 
psoriasis, are able to aggravate or even induce the 
disease. However, since the use of TNF-α antagonists 
has increased, this adverse effect is becoming more 
and more important in the therapeutic management 
of rheumatic patients. In fact, the cases of psoriasis 
developed after administration of anti-TNF-α agents 
are becoming more and more common, and it is in-
creasingly easy to come across one of these cases and 
have to recognize and treat it promptly. Apart from 
the disagreeable nature of this dermopathy, ranging 
from slight predominant cosmetic impairment to se-
vere and diffuse skin eruptions, the major impact of 
this side effect lies in the fact that a considerable per-
centage of patients need either to switch to another 
TNF-α inhibitor (often with recurrence of psoriatic le-
sions) or discontinue anti-TNF-α treatment. This wide 
variation both in the cutaneous manifestations and in 
the response to treatment suggests an individual sus-
ceptibility. Moreover, it highlights the important and 
complex role of TNF-α in the pathogenesis of psoria-
sis, which is not yet completely known, and a better 
pathogenetic understanding would likely finally 
help to define and improve treatment strategies for 
this complication. Bringing back the clinical issues to 
the laboratory bench seems particularly important in 
these cases, in order to fully understand the immuno-
pathogenesis and molecular mechanisms that induce 
the appearance of these paradoxical effects.
Meanwhile, patients should be informed of 
these paradoxical effects prior to the start of anti-
TNF-α treatment, and treating physicians should 
maintain close surveillance of their patients with 
an early referral to a dermatologist in case of side 
effects occurrence. Close cooperation among spe-
cialists is needed to achieve the best treatment.
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